Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 7:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: levothyroxine sodium Clear all
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

NCT03977207
View directory record Official record
Conditions
Thyroid; Functional Disturbance, Hypothyroidism, Hemodialysis
Interventions
Levothyroxine Sodium, Placebos
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 7, 2026, 7:22 AM EDT
Recruiting Phase 2 Interventional

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

NCT05526144
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions
Synthroid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Not applicable Interventional Results available

Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism

NCT02374593
View directory record Official record
Conditions
Congenital Hypothyroidism
Interventions
Levothyroxine, Ultrasound
Drug · Device
Lead sponsor
Erica Eugster
Other
Eligibility
Up to 2 Weeks
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Sep 7, 2026, 7:22 AM EDT
Terminated Phase 4 Interventional Results available

Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy

NCT02946918
View directory record Official record
Conditions
Thyroid Cancer, Postsurgical Hypothyroidism
Interventions
Levothyroxine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 7, 2026, 7:22 AM EDT
Withdrawn Phase 4 Interventional

Levothyroxine in Pregnant SLE Patients

NCT01276782
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Levothyroxine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

NCT03856970
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 7, 2026, 7:22 AM EDT
Recruiting Phase 4 Interventional

Dosing of LT4 in Older Individuals

NCT06073665
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine Sodium
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

NCT05412979
View directory record Official record
Conditions
Hypothyroidism
Interventions
ST-1891, Levothyroxine
Drug
Lead sponsor
Sention Therapeutics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Greenbrae, California • Newhall, California • Denver, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 2Phase 3 Interventional

Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression

NCT01528839
View directory record Official record
Conditions
Bipolar Disorder
Interventions
L-Thyroxine, Placebo
Drug
Lead sponsor
Charite University, Berlin, Germany
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 7, 2026, 7:22 AM EDT
Active, not recruiting Phase 2 Interventional

Treatment of ARDS With Instilled T3

NCT04115514
View directory record Official record
Conditions
ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Interventions
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Edina, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 7, 2026, 7:22 AM EDT
Terminated No phase listed Observational

Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

NCT02567877
View directory record Official record
Conditions
Postsurgical Hypothyroidism, Hypothyroidism
Interventions
thyroidectomy, levothyroxine in thyroidectomy patients
Procedure · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 1 Interventional Results available

Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

NCT02760056
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Liothyronine sodium, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 7, 2026, 7:22 AM EDT
Recruiting Phase 1 Interventional

Levothyroxine Supplementation for Heart Transplant Recipients

NCT06428097
View directory record Official record
Conditions
Heart Transplant Failure, Heart Transplant Infection
Interventions
Levothyroxine, Normal saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg

NCT00647855
View directory record Official record
Conditions
Healthy
Interventions
Levothyroxine Sodium Tablets 300 μg, Synthroid® Tablets 300 μg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 7, 2026, 7:22 AM EDT
Withdrawn Phase 4 Interventional

Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding

NCT02577367
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine
Drug
Lead sponsor
Jocelyne Karam
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 7, 2026, 7:22 AM EDT
Recruiting Phase 2Phase 3 Interventional

Novel Approaches to the Treatment of Hypothyroidism

NCT06731764
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine, Levothyroxine/Liothyronine once daily, Levothyroxine/Liothyronine twice daily
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Thyroid and Glucose and Energy Metabolism

NCT00106119
View directory record Official record
Conditions
Thyroid Diseases
Interventions
Liothyronine and Levothyroxine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 4 Interventional Results available

Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism

NCT04288115
View directory record Official record
Conditions
Subclinical Hypothyroidism
Interventions
Levothyroxine, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
North Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 7, 2026, 7:22 AM EDT
Withdrawn Phase 3 Interventional

Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage

NCT03390530
View directory record Official record
Conditions
Intraventricular Hemorrhage of Prematurity
Interventions
Thyroxine, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
3 Days to 6 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Energy Metabolism in Thyroidectomized Patients

NCT04782856
View directory record Official record
Conditions
Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions
Levothyroxine, Liothyronine, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 7, 2026, 7:22 AM EDT
Terminated Phase 4 Interventional Results available

Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

NCT05228184
View directory record Official record
Conditions
Congenital Hypothyroidism
Interventions
Tirosint®-SOL, Levothyroxine Sodium
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
1 Day to 9 Months
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 7, 2026, 7:22 AM EDT
Completed Phase 3 Interventional

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

NCT05894954
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 7, 2026, 7:22 AM EDT
Terminated Phase 1 Interventional

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy

NCT00788307
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction, laboratory biomarker analysis, Iodine I 131, Iodine I 123
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 7, 2026, 7:22 AM EDT